Skip to content
Search

Latest Stories

GPhC sets criteria for provisional registration of pre-regs; assessment to move online

The General Pharmaceutical Council (GPhC) has decided on the criteria to register pharmacists on a provisional basis as part its response to the COVID-19 pandemic.

The move follows the postponement of registration assessments scheduled for June and September as a result of the virus outbreak.


The regulator added that the assessment is now expected to be held online.

“There were lots of complex issues which we have had to carefully consider, and we have had to balance risks and benefits when deciding the approach,” commented Duncan Rudkin, chief executive of the GPhC.

“The Council’s final decisions have been guided by a set of principles, including maintaining standards for entry to the register to protect patient safety and quality of care, and the importance of maintaining the workforce pipeline so that pharmacy can continue to serve the needs of patients.”

The provisional registration will be valid from 1 July 2020 until 1 July 2021. Pre-registration pharmacist trainees can apply from July and begin to join the register from 1 August, as announced by the regulator late last month.

The criteria include: successfully completing 52 weeks pre-registration training, not having previously failed the registration assessment and having received a final declaration from their tutor confirming that they have met all the performance standards and are safe to be registered provisionally.

Provisionally registered pharmacists need to be employed directly by the organisation or business in which they are working, refraining them from taking up locum assignments.

They must practice under the guidance of a senior pharmacist, and may work as the Responsible Pharmacist.

The GPhC said it will soon issue standards for employers setting out the framework in which pharmacists who are registered provisionally must operate.

The provisionally registered pharmacists are expected to sit for the registration assessment at the first opportunity if they are fit to do so. They must pass the registration assessment in order to remain on the register.

The Council of the GPhC has also agreed in principle to conduct the registration assessment online, taking account of the necessary technical, security, accessibility and content issues. The regulator said it will give a minimum of two months’ notice of the date for the assessment.

Welcoming the measures, the Royal Pharmaceutical Society (RPS) said it will work with the regulator and  pharmacists in its implementation.

“We are pleased that there is now some clarity about what provisional registration looks like so that employers and pre-registration pharmacists can start to move forward and make plans for their future,” commented Gail Fleming, RPS director for education.

“We are keen to ensure that appropriate solutions are found to the examination issue and are pleased to see that the registration assessment is moving online.  We will actively engage with the GPhC to help ensure that this is implemented in as timely a manner as possible.

“We recognise that provisional registrants will face significant challenges, balancing the pressures of exam preparation and practising as pharmacists. RPS will continue to support provisional registrants with a range of products and services.”

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less